Navigating SEC Comment Letters: Non-GAAP Disclosures and Metrics
Inevitably, companies looking to go public will face the prospect of comment letters from the Securities and Exchange Commission (SEC).
The Ultimate Guide to a Life Sciences IPO
The life sciences industry is in the middle of an IPO boom, with the 10 highest-valued biotech IPOs raising $3.
Meet Kelly Provost: A Leader in CFGI’s Life Sciences Capital Markets
Kelly Provost is a leader in CFGI’s Life Sciences Capital Markets practice and has dedicated her career to supporting companies that are trying to cure diseases and save lives, making a difference in the lives of people across the world.
April Coleman: Former SEC Reviewer Spearheading CFGI’s Dedicated IPO Team
Experience is as good as gold in the accounting advisory world, and arguably no one at CFGI has spent as much time working both sides of the advisory/client aisle than Partner April Coleman.
Vor Biopharma Closes Over $203.4 Million Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market
CFGI’s Capital Markets team assisted Vor Biopharma (NASDAQ: VOR) with their initial public offering.
Ortho Clinical Diagnostics Holdings PLC Closes $1.49 Billion Initial Public Offering of Ordinary Shares Trading on the NASDAQ Global Select Market
CFGI’s Capital Markets team assisted Ortho Clinical Diagnostics Holdings PLC (NASDAQ: OCDX) with their initial public offering.
Clene Nanomedicine Inc. Closes Business Combination with SPAC Tottenham Acquisition I Limited
CFGI’s Capital Markets team assisted Clene Nanomedicine (“Clene”) (NYSE: CLNN) with its SPAC merger with Tottenham Acquisition I Limited (“Tottenham”).
indie Semiconductor and Thunder Bridge Acquisition II, Ltd. Close Business Combination
CFGI’s Capital Markets team assisted indie Semiconductor (“indie”) (NYSE: INDI) with its SPAC merger with Thunder Bridge Acquisition II.